$7.03
5.64% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US09058V1035
Symbol
BCRX
Sector
Industry

BioCryst Pharmaceuticals, Inc. Target price 2024 - Analyst rating & recommendation

BioCryst Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
90%
Hold
10%

BioCryst Pharmaceuticals, Inc. Price Target

Target Price $15.10
Price $7.03
Potential
Number of Estimates 10
10 Analysts have issued a price target BioCryst Pharmaceuticals, Inc. 2025 . The average BioCryst Pharmaceuticals, Inc. target price is $15.10. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 9 Analysts recommend BioCryst Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the BioCryst Pharmaceuticals, Inc. stock has an average upside potential 2025 of . Most analysts recommend the BioCryst Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 331.41 444.90
22.37% 34.25%
EBITDA Margin -30.79% 1.17%
43.27% 103.80%
Net Margin -73.75% -17.55%
27.50% 76.20%

8 Analysts have issued a sales forecast BioCryst Pharmaceuticals, Inc. 2024 . The average BioCryst Pharmaceuticals, Inc. sales estimate is

$445m
Unlock
. This is
7.83% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$449m 8.75%
Unlock
, the lowest is
$430m 4.32%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $331m 22.37%
2024
$445m 34.25%
Unlock
2025
$534m 20.10%
Unlock
2026
$622m 16.44%
Unlock
2027
$715m 14.92%
Unlock
2028
$806m 12.72%
Unlock

1 Analyst has issued an EBITDA forecast BioCryst Pharmaceuticals, Inc. 2024 . The average BioCryst Pharmaceuticals, Inc. EBITDA estimate is

$5.2m
Unlock
. This is
113.24% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$5.2m 113.24%
Unlock
, the lowest is
$5.2m 113.24%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-102m 30.58%
2024
$5.2m 105.11%
Unlock
2025
$66.1m 1,167.78%
Unlock

EBITDA Margin

2023 -30.79% 43.27%
2024
1.17% 103.80%
Unlock
2025
12.36% 956.41%
Unlock

10 BioCryst Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average BioCryst Pharmaceuticals, Inc. net profit estimate is

$-78.1m
Unlock
. This is
38.20% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-62.1m 50.82%
Unlock
, the lowest is
$-95.3m 24.59%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-244m 11.28%
2024
$-78.1m 68.05%
Unlock
2025
$-15.3m 80.37%
Unlock
2026
$55.2m 460.27%
Unlock
2027
$154m 179.38%
Unlock
2028
$202m 30.87%
Unlock

Net Margin

2023 -73.75% 27.50%
2024
-17.55% 76.20%
Unlock
2025
-2.87% 83.65%
Unlock
2026
8.88% 409.41%
Unlock
2027
21.58% 143.02%
Unlock
2028
25.06% 16.13%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.18 -0.38
11.28% 67.80%
P/E negative
EV/Sales 4.42

10 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast for earnings per share. The average BioCryst Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.38
Unlock
. This is
37.70% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.30 50.82%
Unlock
, the lowest is
$-0.46 24.59%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.18 11.28%
2024
$-0.38 67.80%
Unlock
2025
$-0.07 81.58%
Unlock
2026
$0.27 485.71%
Unlock
2027
$0.75 177.78%
Unlock
2028
$0.98 30.67%
Unlock

P/E ratio

Current -11.57 191.44%
2024
-18.65 61.19%
Unlock
2025
-95.00 409.38%
Unlock
2026
26.36 127.75%
Unlock
2027
9.44 64.19%
Unlock
2028
7.21 23.62%
Unlock

Based on analysts' sales estimates for 2024, the BioCryst Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.77 3.25%
2024
4.42 7.29%
Unlock
2025
3.68 16.74%
Unlock
2026
3.16 14.12%
Unlock
2027
2.75 12.98%
Unlock
2028
2.44 11.28%
Unlock

P/S ratio

Current 3.53 9.89%
2024
3.27 7.26%
Unlock
2025
2.73 16.74%
Unlock
2026
2.34 14.12%
Unlock
2027
2.04 12.98%
Unlock
2028
1.81 11.28%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today